{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T02:27:56Z","timestamp":1790389676257,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["16K19709"],"award-info":[{"award-number":["16K19709"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["26893052"],"award-info":[{"award-number":["26893052"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jdsjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Dermatological Science"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.jdermsci.2019.09.004","type":"journal-article","created":{"date-parts":[[2019,9,16]],"date-time":"2019-09-16T11:11:28Z","timestamp":1568632288000},"page":"134-142","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Possible therapeutic applicability of galectin-9 in cutaneous T-cell lymphoma"],"prefix":"10.1016","volume":"96","author":[{"given":"Rina","family":"Nakajima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomomitsu","family":"Miyagaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Kamijo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonori","family":"Oka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Shishido-Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiraku","family":"Suga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Sugaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdermsci.2019.09.004_bib0005","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","article-title":"WHO-EORTC classification for cutaneous lymphomas","volume":"105","author":"Willemze","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jdermsci.2019.09.004_bib0010","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1200\/JCO.2015.61.7142","article-title":"Cutaneous lymphoma international consortium study of outcome in advanced stages of Mycosis fungoides and S\u00e9zary syndrome: effect of specific prognostic markers on survival and development of a prognostic model","volume":"33","author":"Scarisbrick","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jdermsci.2019.09.004_bib0015","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1002\/cncr.22252","article-title":"Significant impact of cutaneous T-cell lymphoma on patients\u2019 quality of life: results of a 2005 National Cutaneous Lymphoma Foundation Survey","volume":"107","author":"Demierre","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.jdermsci.2019.09.004_bib0020","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1001\/jama.1992.03480100060031","article-title":"Infections complicating mycosis fungoides and S\u00e9zary syndrome","volume":"267","author":"Axelrod","year":"1992","journal-title":"JAMA"},{"key":"10.1016\/j.jdermsci.2019.09.004_bib0025","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1182\/blood-2015-12-611830","article-title":"How I treat mycosis fungoides and S\u00e9zary syndrome","volume":"127","author":"Whittaker","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jdermsci.2019.09.004_bib0030","doi-asserted-by":"crossref","first-page":"6416","DOI":"10.1074\/jbc.272.10.6416","article-title":"Molecular definition of a novel human galectin which is immunogenic in patients with Hodgkin\u2019s disease","volume":"272","author":"T\u00fcreci","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jdermsci.2019.09.004_bib0035","first-page":"77","article-title":"The role of TIM-containing molecules in airway disease and their potential as therapeutic targets","volume":"5","author":"Vega-Carrascal","year":"2012","journal-title":"J. Inflamm. Res."},{"key":"10.1016\/j.jdermsci.2019.09.004_bib0040","doi-asserted-by":"crossref","first-page":"E430","DOI":"10.3390\/ijms19020430","article-title":"Role of galectins in tumors and in clinical immunotherapy","volume":"19","author":"Chou","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jdermsci.2019.09.004_bib0045","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.clim.2008.01.006","article-title":"Galectin-9 suppresses the generation of Th17, promotes the induction of regulatory T cells, and regulates experimental autoimmune arthritis","volume":"127","author":"Seki","year":"2008","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.jdermsci.2019.09.004_bib0050","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1038\/ni1271","article-title":"The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity","volume":"6","author":"Zhu","year":"2005","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jdermsci.2019.09.004_bib0055","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.cellimm.2011.03.005","article-title":"Tim-3 ligand galectin-9 reduces IL-17 level and accelerates Klebsiella pneumoniae infection","volume":"269","author":"Wang","year":"2011","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.jdermsci.2019.09.004_bib0060","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.cellimm.2008.01.006","article-title":"The Tim-3 ligand galectin-9 negatively regulates CD8+ alloreactive T cell and prolongs survival of skin graft","volume":"250","author":"Wang","year":"2007","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.jdermsci.2019.09.004_bib0065","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/1479-5876-11-215","article-title":"Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer","volume":"11","author":"Guo","year":"2013","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.jdermsci.2019.09.004_bib0070","doi-asserted-by":"crossref","first-page":"15659","DOI":"10.1038\/srep15659","article-title":"Apoptosis of tumor infiltrating effector TIM-3+CD8+ T cells in colon cancer","volume":"5","author":"Kang","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jdermsci.2019.09.004_bib0075","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1038\/s41388-018-0140-4","article-title":"Tumor cell-intrinsic Tim-3 promotes liver cancer via NF-\u03baB\/IL-6\/STAT3 axis","volume":"37","author":"Zhang","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.jdermsci.2019.09.004_bib0080","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3390\/ijms18010074","article-title":"Cancer therapy due to apoptosis: Galectin-9","volume":"18","author":"Fujita","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jdermsci.2019.09.004_bib0085","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1158\/1541-7786.MCR-10-0040","article-title":"Targeting activating transcription factor 3 by Galectin-9 induces apoptosis and overcomes various types of treatment resistance in chronic myelogenous leukemia","volume":"8","author":"Kuroda","year":"2010","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.jdermsci.2019.09.004_bib0090","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/leu.2010.25","article-title":"Galectin-9 exhibits anti-myeloma activity through JNK and p38 MAP kinase pathways","volume":"24","author":"Kobayashi","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.jdermsci.2019.09.004_bib0095","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.3892\/ijo.2015.2941","article-title":"Galectin-9 suppresses the growth of hepatocellular carcinoma via apoptosis in vitro and in vivo","volume":"46","author":"Fujita","year":"2015","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.jdermsci.2019.09.004_bib0100","doi-asserted-by":"crossref","first-page":"851","DOI":"10.3892\/or.2015.4452","article-title":"Galectin-9 suppresses the proliferation of gastric cancer cells in vitro","volume":"35","author":"Takano","year":"2016","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.jdermsci.2019.09.004_bib0105","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/glycob\/12.2.111","article-title":"Regulation of galectin-9 expression and release in Jurkat T cell line cells","volume":"12","author":"Chabot","year":"2002","journal-title":"Glycobiology"},{"key":"10.1016\/j.jdermsci.2019.09.004_bib0110","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jdermsci.2019.09.004_bib0115","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1093\/jb\/mvm019","article-title":"Characterization of galectin-9-induced death of Jurkat T cells","volume":"141","author":"Lu","year":"2007","journal-title":"J. Biochem."},{"key":"10.1016\/j.jdermsci.2019.09.004_bib0120","doi-asserted-by":"crossref","first-page":"506","DOI":"10.3892\/or.2017.5689","article-title":"Effects of galectin-9 on apoptosis, cell cycle and autophagy in human esophageal adenocarcinoma cells","volume":"38","author":"Akashi","year":"2017","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.jdermsci.2019.09.004_bib0125","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.4049\/jimmunol.170.7.3631","article-title":"Galectin-9 induces apoptosis through the calcium-calpain-caspase-1 pathway","volume":"170","author":"Kashio","year":"2003","journal-title":"J. Immunol."},{"key":"10.1016\/j.jdermsci.2019.09.004_bib0130","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1111\/j.1600-0625.2010.01138.x","article-title":"A novel xenograft model of cutaneous T-cell lymphoma","volume":"19","author":"Krejsgaard","year":"2010","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.jdermsci.2019.09.004_bib0135","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s004320000207","article-title":"Comprehensive galectin fingerprinting in a panel of 61 human tumor cell lines by RT-PCR and its implications for diagnostic and therapeutic procedures","volume":"127","author":"Lahm","year":"2001","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.jdermsci.2019.09.004_bib0140","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.3892\/ol.2016.4142","article-title":"Expression of the galectin-9-Tim-3 pathway in glioma tissues is associated with the clinical manifestations of glioma","volume":"11","author":"Liu","year":"2016","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.jdermsci.2019.09.004_bib0145","article-title":"Reduced expression of Galectin-9 contributes to a poor outcome in colon cancer by inhibiting NK cell chemotaxis partially through the Rho\/ROCK1 signaling pathway","volume":"11","author":"Wang","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jdermsci.2019.09.004_bib0150","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0081799","article-title":"Decreased galectin-9 and increased Tim-3 expression are related to poor prognosis in gastric cancer","volume":"8","author":"Jiang","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jdermsci.2019.09.004_bib0155","doi-asserted-by":"crossref","first-page":"8543","DOI":"10.1038\/sj.onc.1207107","article-title":"A decade of caspases","volume":"22","author":"Degterev","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.jdermsci.2019.09.004_bib0160","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1084\/jem.20100637","article-title":"Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients","volume":"207","author":"Fourcade","year":"2010","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jdermsci.2019.09.004_bib0165","article-title":"TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression","volume":"7","author":"Gao","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jdermsci.2019.09.004_bib0170","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1084\/jem.20100643","article-title":"Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity","volume":"207","author":"Sakuishi","year":"2010","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jdermsci.2019.09.004_bib0175","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/ni988","article-title":"Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance","volume":"4","author":"Sabatos","year":"2003","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jdermsci.2019.09.004_bib0180","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/1074-7613(95)90125-6","article-title":"Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4","volume":"3","author":"Tivol","year":"1995","journal-title":"Immunity"},{"key":"10.1016\/j.jdermsci.2019.09.004_bib0185","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1074-7613(00)80089-8","article-title":"Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor","volume":"11","author":"Nishimura","year":"1999","journal-title":"Immunity"},{"key":"10.1016\/j.jdermsci.2019.09.004_bib0190","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1158\/0008-5472.CAN-11-0096","article-title":"Anti-TIM3 antibody promotes T cell IFN-\u03b3-mediated antitumor immunity and suppresses established tumors","volume":"71","author":"Ngiow","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.jdermsci.2019.09.004_bib0195","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.3892\/or.2015.4197","article-title":"Galectin-9 suppresses cholangiocarcinoma cell proliferation by inducing apoptosis but not cell cycle arrest","volume":"34","author":"Kobayashi","year":"2015","journal-title":"Oncol. Rep."}],"container-title":["Journal of Dermatological Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923181119302944?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923181119302944?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T11:25:25Z","timestamp":1785151525000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923181119302944"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["S0923181119302944"],"URL":"https:\/\/doi.org\/10.1016\/j.jdermsci.2019.09.004","relation":{},"ISSN":["0923-1811"],"issn-type":[{"value":"0923-1811","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Possible therapeutic applicability of galectin-9 in cutaneous T-cell lymphoma","name":"articletitle","label":"Article Title"},{"value":"Journal of Dermatological Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdermsci.2019.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Japanese Society for Investigative Dermatology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}